Regeneration of Bronchial Epithelium During Chronic Obstructive Pulmonary Disease (EPITHREGENCOPD)

August 16, 2016 updated by: CHU de Reims
Airway epithelium integrity is essential to maintain its role of mechanical and functional barrier. Recurrent epithelial injuries require a complex mechanism of repair to restore its integrity. In chronic obstructive pulmonary disease (COPD), an abnormal airway epithelial repair may participate in airway remodelling. The objective was to determine if airway epithelial wound repair of airway epithelium is abnormal in COPD.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Patients scheduled for lung resection were prospectively recruited. Demographic, clinical data and pulmonary function tests results were recorded. Emphysema was visually scored and histological remodelling features were noted. Primary bronchial epithelial cells (BEC) were extracted and cultured for wound closure assay. The investigators determined the mean speed of wound closure (MSWC) and cell proliferation index, matrix metalloprotease (MMP)-2, MMP-9 and cytokines levels in supernatants of BEC 18 hours after cell wounding. In a subset of patients, bronchiolar epithelial cells were also cultured for wound closure assay for MSWC analyze.

Study Type

Observational

Enrollment (Actual)

25

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Reims, France, 51092
        • CHU de Reims

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients scheduled for lung resection for cancer

Description

Inclusion Criteria:

6 Patients scheduled for lung resection for cancer

Exclusion Criteria:

  • Patients with asthma, cystic fibrosis, bronchiectasis or pulmonary fibrosis were excluded

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
patients with COPD
Other: bronchial epithelial cell culture
patients without COPD
Other: bronchial epithelial cell culture

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Mean speed of wound closure (MSWC) of wounded bronchial epithelial cell culture obtained from COPD and control patients
Time Frame: hour 18
hour 18

Secondary Outcome Measures

Outcome Measure
Time Frame
Cell proliferation index in supernatants of bronchial epithelial cells 18 hours after cell wounding.
Time Frame: hour 18
hour 18
Matrix metalloprotease (MMP)-2 level in supernatants of bronchial epithelial cells 18 hours after cell wounding.
Time Frame: hour 18
hour 18
Matrix metalloprotease (MMP)-9 level in supernatants of bronchial epithelial cells 18 hours after cell wounding.
Time Frame: hour 18
hour 18
Cytokines levels in supernatants of bronchial epithelial cells 18 hours after cell wounding.
Time Frame: hour 18
hour 18

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

CHU de Reims

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2012

Primary Completion (Actual)

December 1, 2013

Study Completion (Actual)

May 1, 2014

Study Registration Dates

First Submitted

August 10, 2016

First Submitted That Met QC Criteria

August 16, 2016

First Posted (Estimate)

August 22, 2016

Study Record Updates

Last Update Posted (Estimate)

August 22, 2016

Last Update Submitted That Met QC Criteria

August 16, 2016

Last Verified

August 1, 2016

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PA11017

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COPD

Clinical Trials on bronchial epithelial cell culture

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe